Christina S. Baik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina S. Baik has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Jyoti D. Patel
Northwestern University, Chicago, IL
23 shared publications - Lova Sun
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
23 shared publications - Natasha B. Leighl
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
23 shared publications - Xiuning Le
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
20 shared publications - Zofia Piotrowska
Massachusetts General Hospital 3 Boston, Massachusetts
20 shared publications - Alena Zalutskaya
Blueprint Medicines Corporation, Cambridge, Massachusetts
18 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU-451 brain penetration and intracranial efficacy. A, Total and free BLU-451 plasma and brain levels at 0.5 hour, 1 hour, and 3 hours after a single oral dose of BLU-451 at 20 mg/kg dose in BALB/c mice. Data represent the average of three animals ± SEM. The Kp,brain and Kp,uu,brain values were determined as described in the “Methods” section. B–D, PC9-Luc intracranial injection model in BALB/c nude mice orally dosed once daily with BLU-451 at 2.5 or 25 mg/kg. Visualization of whole-body tumor burden at days 0, 10, and 19 after treatment initiation (B). Total bioluminescence after treatment initiation (C). Visualization of tumor burden in dissected spinal cord (top) and brain (bottom) at day 19 after treatment initiation (D). E–G, PC9-Luc intracarotid injection model in BALB/c nude mice orally dosed once daily with BLU-451 at 1, 2.5, or 25 mg/kg, osimertinib at 25 mg/kg, or erlotinib at 15 mg/kg. Visualization of whole-body tumor burden at days 0, 10, and 20 after treatment initiation (E). Total head bioluminescence after treatment initiation (F). Bioluminescence in dissected brain at day 20 after treatment initiation (G). Images in B, D, and E are representative of 10 animals. Images for all animals are shown in Supplementary Figs. S7 and S8. Data in C, F, and G represent the average of 10 animals ± SEM; log-normal Brown–Forsythe and Welch ANOVA with the Dunnett T3 multiple comparisons test; ***, P < 0.001; ****, P < 0.0001. Groups not connected by the same letter (a, b, c, and d) are significantly different from each other (P < 0.05). Kp,brain, AUCbrain/AUCplasma; Kp,uu,brain, Kp,brain × fu,brain/fu,plasma.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU-451 brain penetration and intracranial efficacy. A, Total and free BLU-451 plasma and brain levels at 0.5 hour, 1 hour, and 3 hours after a single oral dose of BLU-451 at 20 mg/kg dose in BALB/c mice. Data represent the average of three animals ± SEM. The Kp,brain and Kp,uu,brain values were determined as described in the “Methods” section. B–D, PC9-Luc intracranial injection model in BALB/c nude mice orally dosed once daily with BLU-451 at 2.5 or 25 mg/kg. Visualization of whole-body tumor burden at days 0, 10, and 19 after treatment initiation (B). Total bioluminescence after treatment initiation (C). Visualization of tumor burden in dissected spinal cord (top) and brain (bottom) at day 19 after treatment initiation (D). E–G, PC9-Luc intracarotid injection model in BALB/c nude mice orally dosed once daily with BLU-451 at 1, 2.5, or 25 mg/kg, osimertinib at 25 mg/kg, or erlotinib at 15 mg/kg. Visualization of whole-body tumor burden at days 0, 10, and 20 after treatment initiation (E). Total head bioluminescence after treatment initiation (F). Bioluminescence in dissected brain at day 20 after treatment initiation (G). Images in B, D, and E are representative of 10 animals. Images for all animals are shown in Supplementary Figs. S7 and S8. Data in C, F, and G represent the average of 10 animals ± SEM; log-normal Brown–Forsythe and Welch ANOVA with the Dunnett T3 multiple comparisons test; ***, P < 0.001; ****, P < 0.0001. Groups not connected by the same letter (a, b, c, and d) are significantly different from each other (P < 0.05). Kp,brain, AUCbrain/AUCplasma; Kp,uu,brain, Kp,brain × fu,brain/fu,plasma.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU-451 demonstrates early clinical activity. Images of target lesions in the brain (patient case 1) and lung (patient case 2) are shown at baseline, first response at 7 weeks, and confirmatory response at 11 weeks.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU-451 demonstrates early clinical activity. Images of target lesions in the brain (patient case 1) and lung (patient case 2) are shown at baseline, first response at 7 weeks, and confirmatory response at 11 weeks.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
In vivo antitumor activity of BLU-451 in uncommon EGFR PDX and Ba/F3 mouse tumor models. A, Tumor growth in the LU0387 PDX model carrying the EGFR exon 20 insertion H773insNPH. B, Tumor growth in the LXFE2478 PDX model carrying the EGFR exon 20 insertion V769insASV. C, Tumor growth in the EGFR exon 20 insertion V769insASV Ba/F3 tumor model. D, Tumor growth in the EGFR G719S Ba/F3 tumor model. Mice were orally dosed once daily with BLU-451 at 10, 25, or 50 mg/kg, osimertinib at 14 mg/kg, and afatinib at 7.5 mg/kg as indicated. Data represent the average ± SEM of 10 (A, B, and D) or 9 (C) animals per group; Brown–Forsythe and Welch ANOVA with the Dunnett T3 multiple comparisons test; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
In vivo antitumor activity of BLU-451 in uncommon EGFR PDX and Ba/F3 mouse tumor models. A, Tumor growth in the LU0387 PDX model carrying the EGFR exon 20 insertion H773insNPH. B, Tumor growth in the LXFE2478 PDX model carrying the EGFR exon 20 insertion V769insASV. C, Tumor growth in the EGFR exon 20 insertion V769insASV Ba/F3 tumor model. D, Tumor growth in the EGFR G719S Ba/F3 tumor model. Mice were orally dosed once daily with BLU-451 at 10, 25, or 50 mg/kg, osimertinib at 14 mg/kg, and afatinib at 7.5 mg/kg as indicated. Data represent the average ± SEM of 10 (A, B, and D) or 9 (C) animals per group; Brown–Forsythe and Welch ANOVA with the Dunnett T3 multiple comparisons test; ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Effect of BLU451 treatment on tumor growth in uncommon EGFR PDX and BaF3 mouse tumor models
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Effect of BLU451 treatment on tumor growth in uncommon EGFR PDX and BaF3 mouse tumor models
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Kinome tree showing the kinase selectivity of BLU451
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Kinome tree showing the kinase selectivity of BLU451
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
CtDNA profiling in a patient with stage IVB NSCLC with EGFR exon 20 insertion mutation
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
CtDNA profiling in a patient with stage IVB NSCLC with EGFR exon 20 insertion mutation
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU451 potency and selectivity against BaF3 cells expressing EGFR variants from different subtypes
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU451 potency and selectivity against BaF3 cells expressing EGFR variants from different subtypes
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Effect of BLU451 treatment on body weight in in vivo tumor models
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Effect of BLU451 treatment on body weight in in vivo tumor models
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU451 pharmacokinetic analysis in BALBc mice after repeated dosing
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
BLU451 pharmacokinetic analysis in BALBc mice after repeated dosing
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Images of the PC9luciferase intracranial model showing whole-body images and ex vivo images of spinal cord and brain samples
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor against Uncommon EGFR Mutations
Images of the PC9luciferase intracranial model showing whole-body images and ex vivo images of spinal cord and brain samples